Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody targeting the CD70 antibody. Vorsetuzumab has anticancer activity and can enhance the macrophage-associated phagocytosis of kidney cancer cells and inhibit Burkitt lymphoma.

体外实验中，vorsetuzumab（10 μg/mL；2 h）增强了巨噬细胞对肾癌细胞的依赖性吞噬作用[1]。Vorsetuzumab（10 μg/mL；2 h）可进一步开发为针对人类CD70/KWAR23的双特异性抗体。结果表明，KWAR23在四种肾癌细胞系（RCC4、RCC10、TK10和Caki-1）中适度诱导了巨噬细胞的吞噬作用[1]。

在SRG小鼠中，vorsetuzumab（10 mg/kg；i.p.；每隔一天；共12天）抑制了Burkitt's淋巴瘤细胞的增长[1]。